Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rent the Runway Inc (RENT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Rent the Runway IncTrade
Travere Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Rent the Runway Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Rent the Runway Inc trades at $1.71 (market cap $61.07M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 79.9× Rent the Runway Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.

RENTTVTX
Market Cap
$61.07M$4.88B
Volume
80,5951,668,577
Sector
Consumer CyclicalHealth
52-Week High
$9.39$67.52
52-Week Low
$1.55$26.79
Typical Hold Time
56 Days0 Days
Enterprise Value
$228.07M$5.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rent the Runway Inc

Rent the Runway (RENT) trades at $1.71, down 6.56% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with a gross margin of 74.73%, though net income was -$69.90M. Recent news includes a CEO appointment and multiple law firm investigations into investor claims.

The outlook remains challenging with negative equity and high debt, but improving margins and projected 2026 profitability offer potential. Risks include legal scrutiny and financial leverage, while analyst consensus is cautiously optimistic with 42% buy ratings. Stock performance hinges on execution of turnaround efforts.

Travere Therapeutics Inc. Common Stock

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RENT

No sentiment data available yet.

TVTX
100% Buy0% Sell
Avg holding period · 0 Days

About Rent the Runway Inc

Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.

Read more on RENT →

About Travere Therapeutics Inc. Common Stock

Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.

Read more on TVTX →